HDAC9 and cancer: The chemical space for novel ZBGs is expanding and shows promising results in the direction of specific HDAC protein member selectivity, which can open new therapeutic avenues to limit negative side effects or unwanted toxicity and to target specific HDAC disease-driving family members in cancer, autoimmunity, or chronic inflammatory diseases.